Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 8/20 | 0.40 |
| ▸ | PARP1 | P09874 | 6/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | SPR | P35270 | 3/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | PAK4 | O96013 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15287378 | 0.72 | PDPK1 (0.37) | ACVR1PARP1PDPK1AURKAPRKACA | |
| SCHEMBL3134286 | 0.72 | ALDH1A1 (0.33) | ACVR1KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL2351222 | 0.72 | — | — | |
| SCHEMBL13981701 | 0.68 | BRD4 (0.36) | ACVR1PARP1PDPK1CA12ALOX15 | |
| SCHEMBL18689758 | 0.67 | SPR (0.47) | PARP1SPR | |
| SCHEMBL15904910 | 0.66 | PARP1 (0.43) | ACVR1MAP4K4PARP1PDPK1CA12 | |
| SCHEMBL24458554 | 0.65 | NR1H2 (0.33) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL4052191 | 0.65 | PARP1 (0.39) | ACVR1MAP4K4PARP1PDPK1CA12 | |
| SCHEMBL21199524 | 0.65 | PARP1 (0.35) | PARP1SPR | |
| SCHEMBL4052150 | 0.65 | NR1H2 (0.36) | ACVR1PARP1TNKS2PIM1RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563094-B | (hetero) aryl-substituted piperidinyl derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2022-03-18 | — | — | CN | claimed |
| US-8420810-B2 | Bicyclic heterocyclic compound | Ono Pharmaceutical, Co., Ltd. (JP) | 2013-04-16 | — | — | US | claimed |
| US-20100137318-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-03 | — | — | US | claimed |
| EP-2154139-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2010-02-17 | — | — | EP | claimed |
| CN-120309618-A | Synthesis method of pyrrolo [2,1-f ] [1,2,4] triazin-4 (3H) -one | 贵州省瀑植缘生物科技有限公司 | 2025-07-15 | — | — | CN | disclosed |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-25 | — | — | US | disclosed |
| CN-116323566-B | Sulfanone compound and preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-11795171-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795171-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795171-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| CN-116490498-A | Pyrimido cyclic compounds and application thereof in preparation of medicines for treating pains and spinal cord injuries | 南京药石科技股份有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116323566-A | Sulfanone compound and preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20040229877-A1 | Methods of treating p38 kinase-associated conditions with pyrrolotriazine compounds | LEFTHERIS KATERINA (US) | 2004-11-18 | — | — | US | disclosed |
| US-6670357-B2 | Antiinflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-30 | — | — | US | disclosed |
| EP-1363910-A2 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030069244-A1 | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-10 | — | — | US | disclosed |
| EP-1183033-A4 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2002-07-17 | — | — | EP | disclosed |
| WO-2002040486-A2 | METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-05-23 | — | — | WO | disclosed |
| EP-1183033-A1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000071129-A1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069244-A1 | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors | MAPK1, MAPK3, MAPK6 | ACVR1 2590/4885MAP4K4 51/4885PARP1 3046/4885 |
| US-11795171-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, PSMB7 | ACVR1 4455/4885MAP4K4 2061/4885PARP1 1141/4885 |
| US-20040229877-A1 | Methods of treating p38 kinase-associated conditions with pyrrolotriazine compounds | MAPK1, MAPK6, MAPK3 | ACVR1 2925/4885MAP4K4 39/4885PARP1 3118/4885 |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | HAVCR2, HDGF, HCCS | ACVR1 2034/4885MAP4K4 2982/4885PARP1 1220/4885 |
| US-20100137318-A1 | BICYCLIC HETEROCYCLIC COMPOUND | CRH, CRHR1, NR3C2 | ACVR1 2733/4885MAP4K4 2019/4885PARP1 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.